CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
28 mars 2025 07h00 HE
|
CG Oncology Inc.
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Indiaspora and BCG Launch Impact Report on Indian Diaspora in UAE at Indiaspora Forum for Good 2025
06 mars 2025 15h30 HE
|
Indiaspora
The report was unveiled in Abu Dhabi at Indiaspora's Forum for Good on February 24th featuring prominent UAE & US government officials and report partners.
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
26 févr. 2025 08h00 HE
|
CG Oncology Inc.
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Biz2X Announces 2025 Frontiers of Digital Finance (FDF) Conference January 13-14, at University of Miami
17 déc. 2024 06h07 HE
|
Biz2X
NEW YORK and MIAMI, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Biz2X®, a global fintech small business finance platform headquartered in New York that has facilitated over $10 billion in SMB funding to...
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 déc. 2024 16h05 HE
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Proposed Public Offering
11 déc. 2024 06h17 HE
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
02 déc. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30 août 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
06 juin 2024 12h14 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03 mai 2024 11h23 HE
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer